{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:32:08Z","timestamp":1794540728723,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/04xeg9z08","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/04xeg9z08","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","id":[{"id":"https:\/\/ror.org\/04xeg9z08","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ketamine produces immediate antidepressant effects and has inspired research into next-generation treatments. Ketamine also has short term dissociative effects, in which individuals report altered consciousness and perceptions of themselves and their environment. However, whether ketamine\u2019s dissociative side effects are necessary for its antidepressant effects remains unclear. This perspective examines the relationship between dissociative effects and acute and longer-lasting antidepressant response to ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists. Presently, the literature does not support the conclusion that dissociation is necessary for antidepressant response to ketamine. However, further work is needed to explore the relationship between dissociation and antidepressant response at the molecular, biomarker, and psychological levels.<\/jats:p>","DOI":"10.1038\/s41467-020-20190-4","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T06:03:02Z","timestamp":1608616982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":207,"title":["The role of dissociation in ketamine\u2019s antidepressant effects"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5304-0127","authenticated-orcid":false,"given":"Elizabeth D.","family":"Ballard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"20190_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40265-020-01303-1","volume":"80","author":"GS Malhi","year":"2020","unstructured":"Malhi, G. S., Morris, G., Bell, E. & Hamilton, A. A new paradigm for achieving a rapid antidepressant response. Drugs 80, 755\u2013764 (2020).","journal-title":"Drugs"},{"key":"20190_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate, C. A. Jr. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856\u2013864 (2006).","journal-title":"Arch. Gen. Psychiatry"},{"key":"20190_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cpt196563279","volume":"6","author":"EF Domino","year":"1965","unstructured":"Domino, E. F., Chodoff, P. & Corssen, G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin. Pharm. Ther. 6, 279\u2013291 (1965).","journal-title":"Clin. Pharm. Ther."},{"key":"20190_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351\u2013354 (2000).","journal-title":"Biol. Psychiatry"},{"key":"20190_CR5","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough, J. W. et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry 170, 1134\u20131142 (2013).","journal-title":"Am. J. Psychiatry"},{"key":"20190_CR6","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","volume":"25","author":"M Fava","year":"2020","unstructured":"Fava, M. et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol. Psychiatry 25, 1592\u20131603 (2020).","journal-title":"Mol. Psychiatry"},{"key":"20190_CR7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s41380-018-0028-2","volume":"24","author":"AC Nugent","year":"2019","unstructured":"Nugent, A. C. et al. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol. Psychiatry 24, 1040\u20131052 (2019).","journal-title":"Mol. Psychiatry"},{"key":"20190_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","volume":"71","author":"CA Zarate Jr.","year":"2012","unstructured":"Zarate, C. A. Jr. et al. Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71, 939\u2013946 (2012).","journal-title":"Biol. Psychiatry"},{"key":"20190_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados, N. et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67, 793\u2013802 (2010).","journal-title":"Arch. Gen. Psychiatry"},{"key":"20190_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","volume":"71","author":"A Feder","year":"2014","unstructured":"Feder, A. et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71, 681\u2013688 (2014).","journal-title":"JAMA Psychiatry"},{"key":"20190_CR11","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2013.150","volume":"38","author":"CI Rodriguez","year":"2013","unstructured":"Rodriguez, C. I. et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38, 2475\u20132483 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"20190_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/npp.2017.194","volume":"43","author":"JH Taylor","year":"2018","unstructured":"Taylor, J. H. et al. Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology 43, 325\u2013333 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"20190_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","volume":"177","author":"E Dakwar","year":"2020","unstructured":"Dakwar, E. et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am. J. Psychiatry 177, 125\u2013133 (2020).","journal-title":"Am. J. Psychiatry"},{"key":"20190_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","volume":"175","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson, S. T. et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am. J. Psychiatry 175, 150\u2013158 (2017).","journal-title":"Am. J. Psychiatry"},{"key":"20190_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.15585\/mmwr.mm6722a1","volume":"67","author":"DM Stone","year":"2018","unstructured":"Stone, D. M. et al. Vital signs: trends in state suicide rates - United States, 1999-2016 and circumstances contributing to suicide - 27 states, 2015. Morb. Mortal. Wkly Rep. 67, 617\u2013624 (2018).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"20190_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1903305","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J., Farchione, T., Potter, A., Chen, Q. & Temple, R. Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class. N. Engl. J. Med. 381, 1\u20134 (2019).","journal-title":"N. Engl. J. Med."},{"key":"20190_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","volume":"174","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson, S. T. et al. A survey of the cinical, off-label use of ketamine as a treatment for psychiatric disorders. Am. J. Psychiatry 174, 695\u2013696 (2017).","journal-title":"Am. J. Psychiatry"},{"key":"20190_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619\u2013627 (2016).","journal-title":"Lancet Psychiatry"},{"key":"20190_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris, R. L. & Goodwin, G. M. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 42, 2105\u20132113 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"20190_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt, D., Erritzoe, D. & Carhart-Harris, R. Psychedelic psychiatry\u2019s brave new world. Cell 181, 24\u201328 (2020).","journal-title":"Cell"},{"key":"20190_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff, C. M. et al. Psychedelics and psychedelic-assisted psychotherapy. Am. J. Psychiatry 177, 391\u2013410 (2020).","journal-title":"Am. J. Psychiatry"},{"key":"20190_CR22","doi-asserted-by":"crossref","unstructured":"Kadriu, B., et al. Ketamine and serotonergic psychedelics: common mechanisms underlying the effects of rapid-acting antidepressants. Int. J. Neuropsychopharmacol (2020) [Epub ahead of print].","DOI":"10.1093\/ijnp\/pyaa087"},{"key":"20190_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/02791072.2018.1506599","volume":"50","author":"NBS Denomme","year":"2018","unstructured":"Denomme, N. B. S. The Domino effect: Ed Domino\u2019s early studies of psychoactive drugs. J. Psychoact. Drugs 50, 298\u2013305 (2018).","journal-title":"J. Psychoact. Drugs"},{"key":"20190_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal, J. H. et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199\u2013214 (1994). Demonstrates that subanesthetic-dose ketamine can induce psychotomimetic effects in healthy volunteers.","journal-title":"Arch. Gen. Psychiatry"},{"key":"20190_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","volume":"5","author":"B Short","year":"2018","unstructured":"Short, B., Fong, J., Galvez, V., Shelker, W. & Loo, C. K. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 5, 65\u201378 (2018).","journal-title":"Lancet Psychiatry"},{"key":"20190_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","volume":"263","author":"EE Acevedo-Diaz","year":"2020","unstructured":"Acevedo-Diaz, E. E. et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J. Affect Disord. 263, 568\u2013575 (2020).","journal-title":"J. Affect Disord."},{"key":"20190_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jpsychires.2020.06.012","volume":"130","author":"EE Acevedo-Diaz","year":"2020","unstructured":"Acevedo-Diaz, E. E. et al. Can \u2018floating\u2019 predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. J. Psychiatr. Res. 130, 280\u2013285 (2020).","journal-title":"J. Psychiatr. Res."},{"key":"20190_CR28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","volume":"113","author":"EF Domino","year":"2010","unstructured":"Domino, E. F. Taming the ketamine tiger. 1965. Anesthesiology 113, 678\u2013684 (2010).","journal-title":"Anesthesiology"},{"key":"20190_CR29","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959\u2013964 (2010).","journal-title":"Science"},{"key":"20190_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/bs.apha.2020.04.005","volume":"89","author":"K Suzuki","year":"2020","unstructured":"Suzuki, K. & Monteggia, L. M. The role of eEF2 kinase in the rapid antidepressant actions of ketamine. Adv. Pharmacol. 89, 79\u201399 (2020).","journal-title":"Adv. Pharmacol."},{"key":"20190_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","volume":"32","author":"P Zanos","year":"2018","unstructured":"Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A. Jr. & Gould, T. D. Convergent mechanisms underlying rapid antidepressant action. CNS Drugs 32, 197\u2013227 (2018).","journal-title":"CNS Drugs"},{"key":"20190_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neuron.2020.05.015","volume":"106","author":"ET Kavalali","year":"2020","unstructured":"Kavalali, E. T. & Monteggia, L. M. Targetic homeostatic synaptic plasticity for treatment of mood disorders. Neuron 106, 715\u2013726 (2020). Review of homeostatic synaptic plasticity as a potential mechanism of antidepressant effects.","journal-title":"Neuron"},{"key":"20190_CR33","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","volume":"17","author":"B Moghaddam","year":"1997","unstructured":"Moghaddam, B., Adams, B., Verma, A. & Daly, D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921\u20132927 (1997). Preclinical work demonstrating that ketamine increases glutamate, in part by disrupting dopaminergic transmission in the prefrontal cortex.","journal-title":"J. Neurosci."},{"key":"20190_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos, P. et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533, 481\u2013486 (2016). Preclinical work suggesting that a ketamine metabolite is responsible for ketamine\u2019s antidepressant effects and that these effects occur independently of NMDA receptor inhibition.","journal-title":"Nature"},{"key":"20190_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-pharmtox-010617-052811","volume":"59","author":"TD Gould","year":"2019","unstructured":"Gould, T. D., Zarate, C. A. J. & Thompson, S. M. Molecular pharmacology and neurobiology of rapid-acting antidepressants. Annu Rev. Pharmacol. Toxicol. 59, 213\u2013236 (2019).","journal-title":"Annu Rev. Pharmacol. Toxicol."},{"key":"20190_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.conb.2014.12.004","volume":"30","author":"LM Monteggia","year":"2015","unstructured":"Monteggia, L. M. & Zarate, C. A. J. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr. Opin. Neurobiol. 30, 139\u2013143 (2015).","journal-title":"Curr. Opin. Neurobiol."},{"key":"20190_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jad.2014.02.017","volume":"159","author":"DA Luckenbaugh","year":"2014","unstructured":"Luckenbaugh, D. A. et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J. Affect Disord. 159, 56\u201361 (2014). Secondary analysis of clinical trial data suggesting a relationship between ketamine\u2019s antidepressant effects and its dissociative side effects.","journal-title":"J. Affect Disord."},{"key":"20190_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner, J. D. et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J. Trauma Stress 11, 125\u2013136 (1998).","journal-title":"J. Trauma Stress"},{"key":"20190_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2019.12.023","volume":"264","author":"DS Mathai","year":"2020","unstructured":"Mathai, D. S., Meyer, M. J., Storch, E. A. & Kosten, T. R. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. J. Affect Disord. 264, 123\u2013129 (2020). Systematic review demonstrating inconsistent evidence for a relationship between ketamine\u2019s dissociative and antidepressant effects.","journal-title":"J. Affect Disord."},{"key":"20190_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1176\/appi.ajp.2009.09060820","volume":"167","author":"RH Perlis","year":"2010","unstructured":"Perlis, R. H. et al. Assuring that double-blind is blind. Am. J. Psychiatry 167, 250\u2013252 (2010).","journal-title":"Am. J. Psychiatry"},{"key":"20190_CR41","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41386-019-0317-8","volume":"44","author":"ST Wilkinson","year":"2019","unstructured":"Wilkinson, S. T. et al. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology 44, 1233\u20131238 (2019).","journal-title":"Neuropsychopharmacology"},{"key":"20190_CR42","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos, P. et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol. Rev. 70, 621\u2013660 (2018).","journal-title":"Pharmacol. Rev."},{"key":"20190_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jad.2017.09.023","volume":"227","author":"GI van Schalkwyk","year":"2018","unstructured":"van Schalkwyk, G. I., Wilkinson, S. T., Davidson, L., Silverman, W. K. & Sanacora, G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician Administered Dissociative States Scale. J. Affect Disord. 227, 11\u201316 (2018).","journal-title":"J. Affect Disord."},{"key":"20190_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider, F. X. & Kometer, M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat. Rev. Neurosci. 11, 642\u2013651 (2010).","journal-title":"Nat. Rev. Neurosci."},{"key":"20190_CR45","doi-asserted-by":"publisher","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus, E., Gamma, A. & Vollenweider, F. X. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE 5, e12412 (2010).","journal-title":"PLoS ONE"},{"key":"20190_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jad.2019.09.017","volume":"260","author":"NC Salloum","year":"2020","unstructured":"Salloum, N. C. et al. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J. Affect Disord. 260, 131\u2013139 (2020).","journal-title":"J. Affect Disord."},{"key":"20190_CR47","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/mp.2016.249","volume":"22","author":"CA Zarate Jr.","year":"2017","unstructured":"Zarate, C. A. Jr. & Machado-Vieira, R. Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders. Mol. Psychiatry 22, 324\u2013327 (2017).","journal-title":"Mol. Psychiatry"},{"key":"20190_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly, E. J. et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 75, 139\u2013148 (2018).","journal-title":"JAMA Psychiatry"},{"key":"20190_CR49","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly, E. J. et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 76, 893\u2013903 (2019).","journal-title":"JAMA Psychiatry"},{"key":"20190_CR50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","volume":"175","author":"CM Canuso","year":"2018","unstructured":"Canuso, C. M. et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 175, 620\u2013630 (2018).","journal-title":"Am. J. Psychiatry"},{"key":"20190_CR51","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova, V. et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am. J. Psychiatry 176, 428\u2013438 (2019).","journal-title":"Am. J. Psychiatry"},{"key":"20190_CR52","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin, M. et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J. Neuropsychopharmacol. 22, 616\u2013630 (2019).","journal-title":"Int J. Neuropsychopharmacol."},{"key":"20190_CR53","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","volume":"28","author":"SH Preskorn","year":"2008","unstructured":"Preskorn, S. H. et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28, 631\u2013637 (2008).","journal-title":"J. Clin. Psychopharmacol."},{"key":"20190_CR54","first-page":"204","volume":"288","author":"GA Mealing","year":"1999","unstructured":"Mealing, G. A., Lanthorn, T. H., Murray, C. L., Small, D. L. & Morley, P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J. Pharm. Exp. Ther. 288, 204\u2013210 (1999).","journal-title":"J. Pharm. Exp. Ther."},{"key":"20190_CR55","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","volume":"74","author":"CA Zarate Jr.","year":"2013","unstructured":"Zarate, C. A. Jr. et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol. Psychiatry 74, 257\u2013264 (2013).","journal-title":"Biol. Psychiatry"},{"key":"20190_CR56","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/mp.2013.130","volume":"19","author":"G Sanacora","year":"2014","unstructured":"Sanacora, G. et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 19, 978\u2013985 (2014).","journal-title":"Mol. Psychiatry"},{"key":"20190_CR57","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/npp.2016.224","volume":"42","author":"G Sanacora","year":"2017","unstructured":"Sanacora, G. et al. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study. Neuropsychopharmacology 42, 844\u2013853 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"20190_CR58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","volume":"163","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate, C. A. Jr. et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 163, 153\u2013155 (2006).","journal-title":"Am. J. Psychiatry"},{"key":"20190_CR59","doi-asserted-by":"publisher","first-page":"966","DOI":"10.4088\/JCP.12m08252","volume":"74","author":"EG Smith","year":"2013","unstructured":"Smith, E. G. et al. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 74, 966\u2013973 (2013).","journal-title":"J. Clin. Psychiatry"},{"key":"20190_CR60","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","volume":"32","author":"L Ibrahim","year":"2012","unstructured":"Ibrahim, L., et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 32, 551\u2013557 (2012).","journal-title":"J Clin Psychopharmacol"},{"key":"20190_CR61","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HRP.0000000000000183","volume":"26","author":"ID Henter","year":"2018","unstructured":"Henter, I. D., de Sousa, R. T. & Zarate, C. A. Jr. Glutamatergic modulators in depression. Harv. Rev. Psychiatry 26, 307\u2013319 (2018).","journal-title":"Harv. Rev. Psychiatry"},{"key":"20190_CR62","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/ijnp\/pyaa025","volume":"23","author":"LT Park","year":"2020","unstructured":"Park, L. T. et al. A randomized trial of the N-methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression. Int. J. Neuropsychopharmacol. 23, 417\u2013425 (2020).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"20190_CR63","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/01.pra.0000462606.17725.93","volume":"21","author":"S Preskorn","year":"2015","unstructured":"Preskorn, S. et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J. Psychiatr. Pract. 21, 140\u2013149 (2015).","journal-title":"J. Psychiatr. Pract."},{"key":"20190_CR64","unstructured":"Allergan. Allergan announces Phase 3 results for Rapastinel as an adjunctive treatment for major depressive disorder (MDD) Vol. 2020 (Allergan, 2019). https:\/\/www.biospace.com\/article\/releases\/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-\/."},{"key":"20190_CR65","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","volume":"51","author":"J Dore","year":"2019","unstructured":"Dore, J. et al. Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J. Psychoact. Drugs 51, 189\u2013198 (2019).","journal-title":"J. Psychoact. Drugs"},{"key":"20190_CR66","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos, P. & Gould, T. D. Mechanisms of ketamine action as an antidepressant. Mol. Psychiatry 23, 801\u2013811 (2018).","journal-title":"Mol. Psychiatry"},{"key":"20190_CR67","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1073\/pnas.1816071116","volume":"116","author":"EW Lumsden","year":"2019","unstructured":"Lumsden, E. W. et al. Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. Proc. Natl Acad. Sci. USA 116, 5160\u20135169 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"20190_CR68","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41386-020-0663-6","volume":"45","author":"CA Farmer","year":"2020","unstructured":"Farmer, C. A. et al. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology 45, 1398\u20131404 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"20190_CR69","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/bs.apha.2020.05.003","volume":"89","author":"B Kadriu","year":"2020","unstructured":"Kadriu, B. et al. Neurobiological biomarkers of response to ketamine. Special issue: ketamine and rapid acting antidepressants: a new era in the treatment of depression. Adv. Pharmacol. 89, 195\u2013235 (2020).","journal-title":"Adv. Pharmacol."},{"key":"20190_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.69","volume":"2","author":"MJ Gandal","year":"2012","unstructured":"Gandal, M. J. et al. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl. Psychiatry 2, e142 (2012).","journal-title":"Transl. Psychiatry"},{"key":"20190_CR71","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.biopsych.2018.01.027","volume":"84","author":"JW Evans","year":"2018","unstructured":"Evans, J. W. et al. Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration. Biol. Psychiatry 84, 582\u2013590 (2018).","journal-title":"Biol. Psychiatry"},{"key":"20190_CR72","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.nicl.2018.07.006","volume":"20","author":"JL Reed","year":"2018","unstructured":"Reed, J. L. et al. Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. Neuroimage Clin. 20, 92\u2013101 (2018).","journal-title":"Neuroimage Clin."},{"key":"20190_CR73","first-page":"610","volume":"4","author":"JL Reed","year":"2019","unstructured":"Reed, J. L. et al. Effects of ketamine on brain activity during emotional processing: differential findings in depressed versus healthy control participants. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 4, 610\u2013618 (2019).","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"20190_CR74","doi-asserted-by":"publisher","first-page":"109838","DOI":"10.1016\/j.pnpbp.2019.109838","volume":"99","author":"R McMillan","year":"2020","unstructured":"McMillan, R. et al. Simultaneous EEG\/fMRI recorded during ketamine infusion in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 99, 109838 (2020).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"20190_CR75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41586-020-2731-9","volume":"586","author":"S Vesuna","year":"2020","unstructured":"Vesuna, S. et al. Deep posteromedial cortical rhythm in dissociation. Nature 586, 87\u201394 (2020).Preclinical analysis of ketamine and PCP models suggesting that dissociation is associated with rhythms within layer 5 of the retrosplenial cortex; similar results were found in the posteromedial cortex of a human patient with focal epilepsy.","journal-title":"Nature"},{"key":"20190_CR76","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-clinpsy-050212-185531","volume":"9","author":"D Spiegel","year":"2013","unstructured":"Spiegel, D. et al. Dissociative disorders in DSM-5. Annu Rev. Clin. Psychol. 9, 299\u2013326 (2013).","journal-title":"Annu Rev. Clin. Psychol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20190-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20190-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20190-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T21:11:16Z","timestamp":1670274676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20190-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["20190"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-20190-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"assertion":[{"value":"29 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A.Z. is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2<i>R<\/i>,6<i>R<\/i>)-hydroxynorketamine, (<i>S<\/i>)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (<i>R,S<\/i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2<i>R<\/i>,6<i>R<\/i>)-hydroxynorketamine and (2<i>S<\/i>,6<i>S<\/i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. E.D.B. has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6431"}}